Select country set
language
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

Human KL-6 ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA
  • Other names:Sialylated Carbohydrate Antigen, Krebs von den Lungen-6, Mucin-1, MUC-1, Breast carcinoma-associated antigen DF3, Cancer antigen 15-3, CA 15-3, Carcinoma-associated mucin, Episialin, H23AG, Krebs von den Lungen-6, PEMT, Peanut-reactive urinary mucin, PUM, Polymorphic epithelial mucin, PEM, Tumor-associated epithelial membrane antigen, EMA, Tumor-associated mucin, CD227
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RBL004R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA

Applications

Serum, Plasma

Sample Requirements

1 µl/well

Shipping

Shipped on blue ice packs. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Range

0.156 - 10 U/ml

Limit of Detection

0.04 U/ml

Intra-assay (Within-Run)

n = 8
CV = 2%

Inter-assay (Run-to-Run)

n = 8
CV = 2%

Spiking Recovery

100.8%

Dilution Linearity

102.7%

Summary

Features

It is intended for research use only

The total assay time is less than 3 hours

The kit measures KL-6

Assay format is 96 wells

Quality Controls are human serum based

Standard is a recombinant protein

Components of the kit are provided ready to use, concentrated or dried

Research topic

Immune Response, Infection and Inflammation, Oncology, Pulmonary diseases, COVID-19

Summary

Interstitial lung diseases (ILD) are a group of lung disorders characterized by interstitial lung thickening. Krebs von den Lungen-6 (KL-6) is a 200 kDa glycoprotein that is predominantly expressed by damaged alveolar type II cells, and it has been proposed as a potential biomarker of different ILD. KL-6 has profibrotic and anti-apoptotic effects on lung fibroblasts and reflects the degree and severity of alveolar epithelial injury. KL-6 is predictive biomarker useful in the clinical management of ILD patients, particularly in patients with severe fibrotic lung disorders. Serum KL-6 levels were also found elevated in Rheumatoid Arthritis – Associated IDL patients, and the levels positively correlated with HRCT fibrosis score.

Summary References (15)

References to KL-6

  • Arase Y, Ikeda K, Suzuki Y, Kobayashi M, Suzuki F, Akuta N, Sezaki H, Hosaka T, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H. Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin. Intern Med. 2007;46 (15):1155-60
  • Fujiwara Y, Kiura K, Toyooka S, Hotta K, Tabata M, Takigawa N, Soh J, Tanimoto Y, Kanehiro A, Kato K, Date H, Tanimoto M. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer. 2008 Jan;59 (1):81-7
  • Hamada H, Kohno N, Akiyama M, Hiwada K. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest. 1992 Mar;101 (3):858-60
  • Kida Y, Maeshima E, Furukawa K, Ichikawa T, Goda M, Ichinose M. A case of polymyositis with a significantly high level of KL-6 associated with pancreatic cancer. Mod Rheumatol. 2007;17 (3):262-4
  • Kikuchi N, Ishii Y, Ohtsuka M. Serum KL-6 levels and acute lung inflammation. Intern Med. 2007;46 (6):335; author reply 337
  • Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995 Aug;108 (2):311-5
  • Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest. 1996 May;109 (5):1276-82
  • Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol. 1988 Sep;18 (3):203-16
  • Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, Yokoyama A, Hamada H, Fujioka S, Hiwada K. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993 Sep;148 (3):637-42
  • Kohno N, Hamada H, Fujioka S, Hiwada K, Yamakido M, Akiyama M. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest. 1992 Jul;102 (1):117-22
  • Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989 Jul;96 (1):68-73
  • Kohno N, Kyoizumi S, Tanabe M, Oyama T, Vossler M, Yamakido M, Akiyama M. Detection of a circulating tumor-associated antigen with a murine monoclonal antibody, LISA 101, selected by reversed indirect enzyme-linked immunosorbent assay. Cancer Res. 1989 Jun 15;49 (12):3412-9
  • Kunitake R, Kuwano K, Yoshida K, Maeyama T, Kawasaki M, Hagimoto N, Hara N. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respiration. 2001;68 (5):488-95
  • Ohtsuki Y, Nakanishi N, Fujita J, Yoshinouchi T, Kobayashi M, Ueda N, Lee GH, Furihata M. Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias. Med Mol Morphol. 2007 Sep;40 (3):163-7
  • Tang W, Guo Q, Qu X, Inagaki Y, Seyama Y, Midorikawa Y, Gai R, Kokudo N, Sugawara Y, Nakata M, Makuuchi M. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma. Oncol Rep. 2007 Apr;17 (4):737-41
Related Products Docs